Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;102(4):490-495.
doi: 10.1111/cen.15185. Epub 2024 Dec 19.

How Does Thyroid Hormone Profile Differ on and Off Replacement Treatment?

Affiliations

How Does Thyroid Hormone Profile Differ on and Off Replacement Treatment?

Adrian H Heald et al. Clin Endocrinol (Oxf). 2025 Apr.

Abstract

Introduction: There continues to be much discussion around optimisation of thyroid hormone status in hypothyroid individuals. We here looked the way that free T4(FT4) and thyroid-stimulating hormone (TSH) related to each other in a large laboratory sample of people who underwent a thyroid function test (TFT), split between those on levothyroxine replacement (monitoring test) and those who underwent a test to check for thyroid hormone imbalance (diagnostic test; not on levothyroxine).

Methods: TFT test (FT4/TSH) results were extracted from the Salford Royal Hospital Laboratory Information Management System during 2009-2012. This was a single site study. Requests includes a tick box for 'on levothyroxine' (yes or no). To minimise comorbidity effects, only samples taken in General Practices were used. For untreated patients only those who had single tests results were used; for treated patients, the median value across all their results was used. Cluster analysis considered an ellipse with centre on median values for log (TSH) and FT4 and the vertex based on 5% and 95% percentile values of both. The percentage of patients falling outside the ellipse boundary was considered for both treated and untreated populations.

Results: The total data set included 290,000 tests on 130,000 individuals. After filtering, FT4/TSH results were used from 12,006 (F 9231/M 2775; age < 60 5850/age ≥ 60 6567) treated patients with 43,846 test results. These were compared to the single results for 43,394 untreated patients (F 24,386/M19,008; age < 60 32,537/age ≥ 60 10,857). Cluster analysis showed for untreated patients, median values for TSH and FT4 were 1.8 mU/L and 15.5 pmol/L, respectively, with 24% of patient results falling outside the untreated 5%/95% percentiles. For treated patients, the median TSH was 2.3 mU/L (+30% vs. untreated) and FT4 was 18.9 pmol/L (+22% vs. untreated), with 22% of treated patients falling outside the treated 5%/95% percentiles. When considered against the untreated limits, 68% of treated results fell outside (split male 63%, female 70% and age < 60 67%, Age ≥ 60 64%).

Conclusion: The current treatment regimens of either low or high dose levothyroxine are not delivering the expected laboratory TFT profiles, with significant numbers of treated patients being well outside the expected values: both TSH and FT4 being significantly higher. This effect appears to be more prevalent in women than men.

Keywords: thyroid hormone profile; treated hypothyroidism; untreated and euthyroid individuals.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Shows FT4 value against log(TSH) for (a) results for patients who have been treated with LT4. Where more than one result was available the median result in each year was applied and (b) Untreated patients who had a single diagnostic test result during the period. The ellipses are centred on median values and x, y based on 5%ile and 95%ile values for TSH and FT4.
Figure 2
Figure 2
Differences between total treated (monitoring test) and untreated (screening test) populations (a) % total population by age group. (b) Median TSH plotted by age group for treated and untreated patients. (c) Median FT4 by age group.

Similar articles

References

    1. Garmendia Madariaga A., Santos Palacios S., Guillén‐Grima F., and Galofré J. C., “The Incidence and Prevalence of Thyroid Dysfunction in Europe: A Meta‐Analysis,” The Journal of Clinical Endocrinology and Metabolism 99, no. 3 (2014): 923–931, 10.1210/jc.2013-2409. - DOI - PubMed
    1. Leng O. and Razvi S., “Hypothyroidism in the Older Population,” Thyroid Research 12, no. 1 (2019): 2, 10.1186/s13044-019-0063-3. - DOI - PMC - PubMed
    1. Chaker L., Bianco A. C., Jonklaas J., and Peeters R. P., “Hypothyroidism,” The Lancet 390, no. 10101 (2017): 1550–1562, 10.1016/s0140-6736(17)30703-1. - DOI - PMC - PubMed
    1. Cooper D. S. and Biondi B., “Subclinical Thyroid Disease,” The Lancet 379, no. 9821 (2012): 1142–1154, 10.1016/S0140-6736(11)60276-6. - DOI - PubMed
    1. “Recommendations | Thyroid Disease: Assessment and Management | Guidance | NICE,” 2024, https://www.nice.org.uk/guidance/ng145/chapter/Recommendations#managing-....